OBJECTIVES: Postimplantation right ventricular dysfunction is associated with increased morbidity and mortality in ventricular assist device (VAD) recipients. This study aimed to determine the preoperative risk factors for severe right heart failure needing biventricular mechanical circulatory support in children with end-stage heart failure.
INTRODUCTION
Ventricular assist device (VAD) has been a beneficial treatment option for paediatric and adult patients with intractable heart failure, mainly as a bridge to transplantation. However, despite the great improvement in VAD technology and growing clinical experience, a significant proportion of the left ventricular assist device (LVAD) recipients developed postoperative right heart failure, which has been demonstrated to adversely affect outcomes [1] . For patients with severe right ventricular dysfunction refractory to standard medical therapy, additional right ventricular assist device (RVAD) implantation needs to be considered [2] . However, even with proper treatment, high mortality is still common in these patients [3] . Prior studies have shown that preplanned implantation of biventricular assist device (BVAD) was associated with improved patient outcomes, when compared with delayed conversion of an LVAD to biventricular mechanical support, thus, highlighting the importance of preimplantation patient selection for BVAD insertion.
Currently, although many risk factors for post-LVAD right ventricular dysfunction in adult VAD candidates have been identified [4] [5] [6] [7] [8] , predictors for severe right heart failure and requirements for biventricular mechanical circulatory support in paediatric recipients have not been fully characterized. Accordingly, we retrospectively reviewed our recent 10-year paediatric VAD experience to determine the preoperative correlates of a need for BVAD use in children with advanced heart failure.
January 1999 and October 2010 were retrospectively identified from a computerized database. Of the included patients, 24 (29%) required additional RVAD support, and the remaining 60 (71%) received isolated LVAD insertion. The study population was followed up until cardiac transplantation, device explantation for myocardial recovery or death on mechanical support. According to the German law, approval from the Ethics Committee was not required for retrospective data analysis, since this kind of study did not vitiate human rights. All parents of those children provided written informed consents for device insertion.
Ventricular assist devices
Multiple VADs were used during the study period. Implanted LVADs included the Berlin Heart EXCOR LVADs (Berlin Heart GmbH, Berlin, Germany; n = 75, 89%), the HeartWare HVAD LVADs (HeartWare Inc., Framingham, MA, USA; n = 7, 8%) and the Berlin Heart Incor LVADs (Berlin Heart GmbH; n = 2, 3%). Regarding RVAD insertion, most of the recipients who required biventricular support were implanted with the Berlin Heart EXCOR RVADs (Berlin Heart GmbH; n = 23, 96%), except one child who received right ventricular support with the Levitronix CentriMag RVAD (Levitronix LLC, Waltham, MA, USA; n = 1, 4%). Details of the surgical procedure, implantation and weaning criteria, and postoperative patient management were published previously [9] [10] [11] .
Data collection
To determine the predictors for the need of biventricular support, preimplantation patient characteristics, laboratory values and haemodynamic data were retrospectively collected, and the differences between BVAD and LVAD recipients were further compared. Eight children with preimplantation singleventricle physiology (two with hypoplastic left heart syndrome, two with single ventricle and the other four after either Fontan or Glenn operations) who required by definition only univentricular support were excluded from the risk factor analysis. The preoperative clinical variables assessed in this study included: patient demographics, aetiology of heart failure, preimplantation support (mechanical ventilation, intensive care unit stay, cardiopulmonary resuscitation [CPR] , renal replacement therapy and mechanical circulatory support before long-term VAD implantation), year of implantation and intravenous medication usage. The preoperative vital signs and cardiopulmonary haemodynamic results included: temperature, systemic blood pressure, heart rate, central venous pressure, pulse oxygen saturation, right and left atrial area, right and left ventricular end-diastolic diameter (RVEDD, LVEDD), short/long (S/L) axis of right ventricle, tricuspid annular plane systolic excursion (TAPSE), right and left ventricular ejection fraction, tricuspid and mitral regurgitation severity, pulmonary artery (PA) and pulmonary capillary wedge pressure, cardiac output and index, pulmonary and systemic vascular resistance and right ventricular stroke work index. For all children, right and left atrial area were indexed to patient's body surface area. RVEDD, LVEDD and TAPSE were expressed by Z-scores based on normal paediatric reference values [12] [13] [14] . The preimplantation laboratory data (obtained <24 h before VAD insertion) included: serum electrolytes, blood glucose concentration, haemoglobin, white blood count, haematocrit, platelet count, international normalization ratio, partial thromboplastin time (PTT), alanine transaminase, aspartate aminotransferase (AST), lactate dehydrogenase, creatine kinase-MB, γ-glutamyl transpeptadase, total bilirubin, albumin, total protein, blood urea nitrogen, serum creatinine and C-reactive protein.
Statistical analysis
Continuous variables were expressed as a mean ± SD and were compared by means of Mann-Whitney U-or Student's t-test, based on the normality of each variable. Categorical variables were represented as frequency distributions and percentages and were compared using χ 2 or Fisher's exact test, as appropriate. All statistical comparisons were two-sided. The variables that were significant by univariate analysis (P ≤ 0.05) were used as potential risk factors and further entered into a logistic regression analysis for multivariate analysis. Potentially confounding factors were evaluated with the main logistic regression model by adding each variable, one at a time, to the main model. KaplanMeier methods were used to calculate survival probability for patients continuing on mechanical support, using a log-rank P-value for significance testing. Patient survival was calculated from the day of VAD implantation until death on mechanical support, censoring at the time of cardiac transplantation or myocardial recovery. All data were analysed using PASW Statistic 18 (SPSS Inc., Chicago, IL, USA).
RESULTS

Patient characteristics
The baseline demographics and clinical characteristics of the study population are shown in Table 1 . The median age was 7 years (mean 7.2 years; range 12 days-18 years), the median weight was 18.8 kg (mean 26.2 kg; range 3.22-88 kg) and the mean body surface area was 0.89 m 2 (median 0.8 m 2 ; range 0.2-2.14 m 2 ). The aetiology of heart failure included 64 (76%) patients with cardiomyopathy, 18 (21%) with congenital heart disease and 2 (2%) with acute myocarditis. The congenital heart disease included transposition of the great arteries (n = 6), complete atrial ventricular septal defect (n = 3), anomalous left coronary artery arising from the PA (n = 2), hypoplastic left heart syndrome (n = 2), single ventricle (n = 2), Ebstein's anomaly (n = 1), interrupted aortic arch (n = 1) and atrial septal defect, ductus arteriosus with left ventricular tumour (n = 1). Most of the children received preoperative mechanical ventilation (68%). Twenty-five children (30%) had preimplantation CPR because of cardiac shock, 15 patients (18%) received temporary circulatory support with intra-aortic balloon pump, extracorporeal membrane oxygenation or centrifugal pump before long-term VAD insertion, and 11 (13%) required preoperative dialysis therapy because of severe renal failure.
Clinical outcomes
Of the 84 children, 45 (54%) were successfully bridged to cardiac transplantation, and 13 (15%) were explanted with myocardial recovery. The overall survival to transplantation or recovery of ventricular function was 69%. The Kaplan-Meier estimates of 30-day and 6-month survival after VAD implantation were 82.9 ± 4.3 and 62.3 ± 6.6%, respectively. Fifty-eight patients (69%) had been discharged from the hospital. The causes of postimplantation death included multi-organ failure in 11 children (42%), stroke in 5 (19%), circulatory failure in 3 (12%), respiratory failure in 2 (8%), infection in 2 (8%), bleeding in 2 (8%) and thrombus in 1 (4%) ( Table 2) .
The median time of mechanical circulatory support was 41 days (mean 72 days; range 1-432 days). The length of VAD support did not differ significantly between the LVAD and BVAD groups (P = 0.87). During mechanical support, 12 of the 24 BVAD recipients died (50%) when compared with 14 of the 60 LVAD patients (23%; P = 0.02). The actuarial survival for children receiving LVAD and BVAD support is depicted in Fig. 1 . Survival at 30 day and 6 month was 86.3 ± 4.9 and 71.2 ± 7.4% for LVAD recipients, respectively; and 74.6 ± 9 and 44.6 ± 11.9% for children requiring biventricular support. Compared with patients supported with BVAD, LVAD recipients had significantly improved survival after VAD implantation (P = 0.04). Of the 24 children requiring biventricular assistance, 15 received pre-planned implantation of BVAD, and RVAD insertions in the other nine recipients were emergent (ranged from 1 to 5 days post-LVAD implantation). Five patients of the planned RVAD group died during mechanical circulatory support (33%) compared with seven in the emergent RVAD group (78%), which indicated a trend towards higher death rates in children receiving non-planned RVAD operation Values are expressed as n (%) unless otherwise specified.
(P = 0.09). There were no significant differences in long-term survival after cardiac transplantation between the LVAD and BVAD groups (87 vs 82% at 2-year post-transplantation, P = 0.67).
Preoperative predictors for BVAD requirement
Preimplantation patient demographics and intravenous medication usage in each group is shown in Table 1 . Preoperative CPR was associated with significantly increased requirement for biventricular support (P = 0.02). There were more BVAD implantations during the earlier study periods (P = 0.04). Patients receiving preoperative milrinone administration had significantly decreased odds of severe right ventricular dysfunction needing biventricular support than those who did not (P = 0.001).
Preoperative requirements for mechanical ventilation, dialysis therapy and short-term mechanical circulatory support were not predictive of the need for additional right ventricular assist. Clinical signs and haemodynamic indexes in each group are presented in Table 3 . Right ventricular dysfunction requiring biventricular assistance developed more frequently in individuals with lower TAPSE Z-score (P = 0.02). A trend was found towards more severe tricuspid regurgitation and decreased systolic pulmonary arterial pressures in children needing RVAD insertion (P = 0.09, 0.07, respectively). There were no significant differences in other indexes between the LVAD and BVAD groups. Several haemodynamic parameters could vary according to different age (such as systematic blood pressure, heart rate and cardiac output). We did an additional analysis by separately evaluating the effects of these factors in infants (<1 year), younger patients (1-5 year) and older patients (≥5 year). These variables remained statistically insignificant through our subgroup analyses.
A preoperative laboratory profile of each group is shown in Table 4 . There was an increased requirement for biventricular support in paediatric patients with higher levels of serum potassium, white blood cell count and AST (P = 0.05. 0.04 and 0.02, respectively). Other laboratory parameters were similar between groups, with trends towards prolonged PTT (P = 0.06), increased 
Multivariate logistic regression
Variables with a univariable P ≤ 0.05 for predicting requirements of biventricular support were further entered into the multivariable logistic regression model, which included preoperative CPR, implantation year, treatment with milrinone, TAPSE Z-score, serum potassium, white blood cell count and AST. Preoperative milrinone administration was found to be the only independent predictors for additional RVAD use, which was associated with decreased needs of biventricular support (odds ratio: 0.1, 95% confidence interval: 0.04-0.64, P = 0.01). Significant advances have occurred in the understanding of the right ventricular function and the use of mechanical circulatory support during the recent years, which might lead to a potential bias to our analysis, given the 10-year study period. We did a subgroup analysis by only including children receiving VAD operation in the last 5 years (n = 41). Five of the 32 children (16%) required additional right ventricular support compared with 4 of the 9 non-milrinone patients (44%), which showed a strong trend towards reduced BVAD use in the milrinone group (P = 0.09), although it did not reach statistical significance, which might be largely due to the relatively small patient number and subsequently limited statistical power. Another analysis was done by including the whole 84 children, and we found that the incidence of additional RVAD implantation was significantly lower in the milrinone group (P = 0.001).
Patient characteristics associated with milrinone use
Fifty-five of the 76 children (72%) have been preoperatively administrated with milrinone (Table 5 ). Milrinone use was more common in children with smaller body mass index (BMI; P = 0.03). Patients with congenital heart disease tended to be overrepresented in the milrinone group (P = 0.02). History of sternotomy was associated with increased milrinone use (P = 0.02). Children who received milrinone were more likely to be treated with epinephrine and nitroprussid preoperatively (P ≤ 0.001, 0.05; respectively). Higher serum potassium was associated with increased milrinone use (P = 0.01). There were no significant differences in other clinical characteristics and preoperative medication requirements between the milrinone and non-milrinone groups.
Because patient BMI, congenital heart disease, previous sternotomy and increased epinephrine and nitroprussid use were associated with milrinone treatment, we further evaluated the possible confounding by these variables in logistic regression models that included each of these factors. Preoperative milrinone use remained statistically significant after adjustment for the potential confounding factors, and the effects of these covariates were insignificant in the multivariate analysis.
The Kaplan-Meier analysis demonstrated that preoperative milrinone use was associated with improved postimplantation survival in paediatric VAD recipients (P = 0.04; Fig. 2 ). Survival at 30 day and 6 month was 96 ± 2.8 and 71.7 ± 8.4% for children in the milrinone group, respectively; compared with 70.3 ± 10.3 and 51.1 ± 1.2% in the non-milrinone group. We did another survival analysis based on the whole study population (n = 84), and milrinone significantly reduced post-VAD death in children (P = 0.04).
DISCUSSION
VAD support is a valid treatment option for paediatric patients with end-stage heart failure. With significant advances in VAD technology and growing paediatric experience, benefits and long-term sequelae in children have been increasingly 5.9 ± 1 5.5 ± 0.9 0.07 Albumin, (g/dl)
3.2 ± 0.6 3 ± 0.7 0.31 C-reactive protein, (mg/dl) 3.3 ± 4.7 2.9 ± 3 0.66
PTT: partial thromboplastin time; ALT: alanine transaminase, AST: aspartate aminotransferase.
appreciated in the recent two decades. Nevertheless, a subset of LVAD recipients would develop right ventricular dysfunction, and additional RVAD implantation might be needed for those unresponsive to pharmacological treatment. The development of right heart failure is often sudden and has multifactorial causes. LVAD induce left ventricle unloading and subsequently decrease the right ventricle afterload [15] ; meanwhile, it also increases the venous return and enhances the right-sided preload [16, 17] .
Additionally, prior study has demonstrated a leftward shift of the interventricular septum during LVAD support, therefore, reducing the contractility of the right heart due to the change in ventricular geometry [18] . Recently, with the improved patient selection, and the significant advancements in VAD technology and postoperative patient management, the incidence of post-LVAD right heart failure has been decreasing. Since the introduction of left apical cannulation Values are expressed as n (%) unless otherwise specified. Abbreviations are listed in Tables 1, 3 to the field of paediatric VAD in 1998, we use this technique whenever possible, because of its superior ability for ventricle unloading compared with left atrial cannulation, which subsequently reduced the afterload of the right ventricle (for this reason, children receiving VAD insertion before 1999 were not included in the present analysis). In combination with proper medical support for patient's right heart, LVAD could provide efficient circulatory support for most of the children with morbid heart failure, and thus, largely decrease the needs for biventricular support. As a consequence, the frequency of BVAD insertion in paediatric population at our institute has been consistently reduced in recent years. Nevertheless, right ventricular dysfunction continues to be a major contributor for postimplantation morbidity and mortality. Children with biventricular failure requiring BVAD insertion might be more severely ill in the preoperative period, and consequently had an increased postoperative mortality rate compared with LVAD patients. In contrast to several published paediatric VAD reports, our study demonstrated that children with biventricular support had significantly worse on VAD survival when compared with LVAD recipients [19, 20] . This finding agreed with large multi-centre adult VAD reports.
Our results further indicated that emergent RVAD implantation was associated with worse clinical outcomes in paediatric patients, which echoed the statements from the adult VAD reports, that candidate selection for BVAD use was the key to improved outcomes. However, the criteria for predicting the need for biventricular support in paediatric population are not well established. In the present study, we conducted a 10-year review of our paediatric VAD experience to determine the risk factors for severe right heart failure requiring RVAD use. By univariate analysis, early implantation year, preoperative CPR, decreased milrinone use and TAPSE Z-score, higher serum potassium, white blood cell count and AST were strongly associated with BVAD placement. Decreased milrinone use was the only independent predictor as identified by the multivariable analysis. To the best of our knowledge, this is the first study to address the preoperative risk stratification for the requirement of BVAD implantation in children.
An important finding of our study was that children receiving milrinone administration had significantly decreased frequency of BVAD implantation. Milrinone, a phosphodiesterase type III inhibitor, which has been used in paediatric population in our centre since the end of the 1990s, is shown to induce vasodilatation and improve myocardial contractility, particularly of the right ventricle, by increasing the intracellular concentration of cyclic adenosine monophosphate in smooth muscle cell and cardiomyocyte, which further leads to an increase in intracellular calcium concentration [21, 22] . Milrinone decreases the right ventricle afterload by dropping left atrial and PA pressures, and causes significant reductions of pulmonary vascular resistance, thus reduces the risk of right heart failure. With the right ventricle contracting adequately, more blood could return to the left heart, and subsequently increase LVAD outflow. A previous study has demonstrated that milrinone increased the right ventricle preload recruitable stroke work and decreased PA pressure [23] . Matthews et al. [6] reported that post-LVAD right heart failure occurred less frequently in LVAD recipients receiving milirone. Kihara et al. [24] have also shown that the use of milrinone could avoid the need of mechanical circulatory support for right ventricular failure after LVAD implantation. Corroborating their findings, our results confirmed that preoperative milrinone use was associated with significantly reduced requirements for BVAD insertion in paediatric patients with advanced heart failure. Therefore, with decreased risks for right heart failure and RVAD requirement, it was reasonable that children receiving milrinone had better survival compared with those who did not.
There are several limitations needed to be described. Firstly, our study was a single-centre retrospective analysis, thus was subject to its inherent bias such as access and accuracy of the data. Secondly, the number of included patients was relatively small, which limited the statistical power of our analysis. Therefore, unadjusted P-values provided for univariable analysis should be interpreted in the context of risk for a Type I error. However, we feel that Bonferroni P-value adjustment in this exploratory analysis may lead to a dismissal of clinically relevant [25] . Furthermore, this limitation was hard to avoid, since the current utilization rate of long-term VAD support in paediatric population is much lower than in adult patients. Finally, there might be children who initially required biventricular support, but did not receive RVAD insertion, either because they did not survive, or the decision of BVAD implantation was not made. This could lead to a potential bias, since those children were categorized as LVAD recipients in our analysis.
CONCLUSION
In conclusion, our results suggested that children with BVAD implantation had significantly worse postimplantation survival compared with LVAD recipients. The multivariate analysis demonstrated that decreased preoperative milrinone use was independently associated with elevated risk of severe right heart failure requiring biventricular mechanical circulatory support in paediatric patients. In addition, preoperative milrinone use was associated with reduced postoperative mortality in children receiving VAD support. Our findings indicated that preoperative milrinone administration might reduce the need for RVAD implantation and further improve the survival of paediatric VAD population.
